Copyright © 2019. Inderes Oy. All rights reserved.

Cantargia

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
30.12.
2020

The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see the company's press releases on 15 and 16 December 2020). Through the share issue, the number of shares and votes in Cantargia increased by 9,100,548. Today, on the last trading day of the month, there are in total 100,192,737 shares and votes in Cantargia.

Tiedotteet
21.12.
2020

In October 2020, Cantargia's AB (publ) nomination committee ahead of the 2021 annual general meeting was appointed in accordance with the guidelines established by the 2020 annual general meeting, Today, Cantargia announces that the committee member Alexander Mata (appointed by Alecta Pensionsförsäkring, Ömsesidigt) resigns from the nomination committee and that Alecta Pensionsförsäkring, Ömsesidigt has appointed Mikael Wiberg as a new member.

Tiedotteet
16.12.
2020

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELSEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW.

Muut analyysit
13.11.
2020

The past few months have been very positive for Cantargia. Most encouraging, in our view, is the recently published and promising interim results for its ongoing phase IIa CANFOUR trial. In its Q3 report, Cantargia repeated the message that it is planning its next steps forward. We argue that these next steps –along with the full results from CANFOUR and the readouts from Novartis's canakinumab trials – represent the next key triggers for the share.

Muut analyysit
14.10.
2020

Over the past few weeks, Cantargia has presented positive interim data from the ongoing CANFOUR trial, which has significantly strengthened our conviction in a successful outcome of ph IIa. The full readout is expected within the coming months, but the company has, on the back of the recent findings, already started planning to advance the development of CAN04 in both NSCLC and PDAC. During Q4, we expect Novartis to present data from its ongoing ph III trial for Canakinumab, which will provide further insight into targeting the IL-1 system for cancer treatment.

Cantargia

Cantargia

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.